Teladoc Health, Inc.

As of September 30, 2026, Teladoc Health, Inc. carries a market capitalization of 1.06B, placing it among publicly traded companies globally. Its enterprise value stands at 1.24B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Teladoc Health, Inc.'s next confirmed earnings release is scheduled for February 23, 2027.

As of September 30, 2026, Teladoc Health, Inc. has 182.25M shares outstanding.

These figures are as of September 30, 2026. The price-to-sales ratio is 0.42, and the price-to-book ratio stands at 0.82.

As of September 30, 2026, Teladoc Health, Inc. trades at an EV/EBITDA multiple of 5.78 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.50 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.24B versus a market cap of 1.06B, with the gap driven by net debt and cash on the balance sheet.

As of September 30, 2026, Teladoc Health, Inc. maintains a current ratio of 0.87, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 79.95, indicating elevated leverage, while an interest coverage ratio of 10.56 demonstrates strong ability to service its debt obligations.

Over the twelve months ended September 30, 2026, Teladoc Health, Inc. posted a negative return on equity (ROE) of -11.52, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -5.48, reflecting losses generated across the asset base. The company generates approximately 440,739.82 in revenue per employee across its workforce of 5,600.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 21.96 indicates how many times Teladoc Health, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended September 30, 2026, Teladoc Health, Inc. recorded an income tax benefit of -3.83M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -158.65M and -154.82M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on November 4, 2026, Teladoc Health, Inc.'s stock has gained approximately 21.55% over the past 52 weeks. The 50-day moving average sits at 6.40, while the 200-day moving average is 6.51.

Over the twelve months ended September 30, 2026, Teladoc Health, Inc. generated 2.47B in revenue and converted that into -154.82M in net income, yielding earnings per share of -0.86. EBITDA reached 214.94M, while operating income came in at -132.32M.

As of September 30, 2026, Teladoc Health, Inc. holds 849.91M in cash and equivalents against 1.04B in total debt, resulting in a net debt position of 147.68M. Total book value stands at 1.29B, with working capital of -189.49M providing operational flexibility.

Teladoc Health, Inc. produced 268.38M in operating cash flow over the twelve months ended September 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled 268.38M - equivalent to 1.49 per share.

Over the twelve months ended September 30, 2026, Teladoc Health, Inc. posted a gross margin of 68.57, reflecting its pricing power and cost economics. The operating margin of -5.36 and net profit margin of -6.27 provide insight into operational efficiency.

These figures cover the twelve months ended September 30, 2026. Free cash flow yield stands at 25.71, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.01, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Teladoc Health, Inc. shareholders.

As of September 30, 2026, Teladoc Health, Inc. has an Altman Z-Score of -15.12, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.